Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Geoffrey Connors MD, FACP
Geoffrey R. Connors MD, FACP Associate Editor
Shyoko Honiden MD, MSc
Shyoko Honiden MD, MSc Editor-in-Chief
Virginia Brady MD
Virginia A. Brady MD Associate Editor
See All Experts
featured
Published in Respiratory Medicine

Expert Opinion / Commentary · December 07, 2020

2020 Top Stories in Respiratory Medicine: Dexamethasone in Hospitalized Patients With COVID-19

Virginia Brady MD

 

 Save  Recommend
 Share

Additional Info

  1. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — final report. N Engl J Med. 2020;383(19):1813-1826.
  2. Annane D, Pastores SM, Rochwerg B, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Intensive Care Med. 2017;43(12):1751-1763.
  3. Villar J, Añón JM, Ferrando C, et al. Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: Study protocol for a randomized controlled superiority trial. Trials. 2020;21(1):717.
  4. RECOVERY Collaborative Group; Horby P, Lim WS, Emberson J, et al. Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. N Engl J Med. 2020 Jul 17. doi:10.1056/NEJMoa2021436. Online ahead of print.
  5. Dequin PF, Heming N, Meziani F, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2020;324(13):1298-1306.
  6. Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324(13):1307-1316.
  7. Angus DC, Derde L, Al-Beidh F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324(13):1317-1329.
  8. Morgan P, Tregunno D, Brydges R, et al. Using a situational awareness global assessment technique for interprofessional obstetrical team training with high fidelity simulation. J Interprof Care. 2015;29(1):13-19.
  9. Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330-1341.

Further Reading

Most Read This Week

Recently Updated